Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-11-08

FDA Approved: FOSRENOL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for FOSRENOL (lanthanum carbonate) submitted by Takeda, resulting in updated labeling for managing hyperphosphatemia in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FOSRENOL (lanthanum carbonate)

Snippet

SUPPL AP for FOSRENOL (LANTHANUM CARBONATE)